Fundz

DarioHealth

NEW YORK, New York, United States · Biotechnology, Fitness, Health Care · 239 employees

DarioHealth Corp. (NASDAQ:DRIO) Dario is changing the way people manage their health, with consumer-friendly digital solutions proven to power lasting behavior change. Dario integrates comprehensive support across a wide range of common and connected health needs, from well-being to chronic condition management, to help our members find long-term success. Billions of data insights from a decade of

Funding history

  • Post-IPO Equity — $23.5M — Jul 2026
  • Funding Round — $23.5M — Jul 2026
  • Venture - Series Unknown — $17.5M — Oct 2025
  • Debt Financing — $32.5M — May 2025
  • Venture - Series Unknown — $18.8M — Jan 2025

Recent signals

  • Jul 22, 2026: Raised $23.5M in Post-IPO Equity
  • Jul 22, 2026: SEC 8-K (1.01): On July 22, 2026, DarioHealth Corp. entered into a Securities Purchase Agreement with institutional investors to conduct a registered direct offering. The Company agreed to issue 2,437,060 shares of common stock at $6.80 per share and pre-funded warrants to purchase 1,017,499 shares at an offering price of $6.7999. The offering is expected to generate approximately $23.5 million in gross proceeds before expenses. This agreement is a significant step for the Company in raising capital for its operations and growth initiatives.
  • Jul 22, 2026: Raised $23.5M in Funding Round
  • Jul 10, 2026: DarioHealth Corp. Appoints Interim Management During Leadership Absence
  • Jul 10, 2026: SEC 8-K (5.02): On July 10, 2026, DarioHealth Corp. announced the extension of Steven Nelson's temporary medical leave of absence as President and Chief Commercial Officer for an indefinite period. During his absence, his responsibilities will be managed by other senior management team members. This change indicates potential restructuring within the company’s leadership, which may impact decision-making processes and strategic direction moving forward.
  • Jul 02, 2026: DarioHealth Corp. Enters Strategic Partnership with Beluga Health to Enhance Chronic Care Management.
  • Nov 10, 2025: DarioHealth Corp. Amends Credit Agreement
  • Nov 05, 2025: SEC 8-K (1.01): On November 5, 2025, DarioHealth Corp. entered into a Credit Agreement Amendment with Callodine Commercial Finance, LLC and other financial institutions. This amendment includes a reset of financial covenants and waives financial-covenant testing for the second and third quarters of 2025. Additionally, it replaces the existing minimum cash covenant, introducing a requirement for a minimum of $10,000,000 in consolidated unencumbered liquid assets. A monthly reporting requirement for 13-week cash flows is established when liquidity falls below $11,000,000, with certain exceptions related to EBITDA. These adjustments are designed to enhance the company's liquidity management amid financial challenges.

See plans & pricing → Track DarioHealth’s funding, hiring, and signals — with verified contacts — on Fundz.